A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination With Adalimumab in Subjects With Moderate to Severe Ulcerative Colitis
Latest Information Update: 15 Sep 2023
At a glance
- Drugs Adalimumab (Primary) ; AMT 101 (Primary) ; Tumour necrosis factor alpha inhibitors
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms MARKET
- Sponsors Applied Molecular Transport
- 13 Sep 2022 Status changed from active, no longer recruiting to completed.
- 07 Aug 2022 This trial has been competed in Netherland, according to European Clinical Trials Database record.
- 06 Jul 2022 According to an Applied Molecular Transport media release, the company will host a live investor conference call and webcast today.